Table 4. Studies on SBRT for OMPC patients.
| Reference | Year | No. of patients/met. | No. of met. | Met. location | Castration sensitivity | Radiotherapy | Treatment outcomes | |
|---|---|---|---|---|---|---|---|---|
| PFS | ADTFS | |||||||
| Prospective | ||||||||
| Phillips et al. (ORIOLE) [24] | 2020 | 54/72 | ≤3 | LN = 33% | 100% | SBRT with 19.5 to 48.0 Gy in 1 to 3 fractions | Median in SBRT arm was not reached after 18.8 months of FU vs 5.8 months in observation arm | N.A. |
| Bone = 21% | ||||||||
| Siva et al. [21] | 2018 | 33/50 | ≤3 | LN = 36.4% | 67% | SFRS with 20 Gy | 1-yr: 58% | 2-yr: 48% |
| Bone = 60.6% | 2-yr: 39% | |||||||
| Both = 3.0% | ||||||||
| Ost et al. (STOMP) [2] | 2017 | 62/116 | ≤3 | LN = 54.8% | 100% | SBRT in 80.6% | Median 10 months in MDT arm vs 6 months in surveillance arm | Median 21 months in MDT arm vs 13 months in surveillance arm |
| Non-nodal = 45.2% | ||||||||
| Retrospective | ||||||||
| Hurmuz et al. [31] | 2020 | 176/353 | ≤5 | LN = 34.7% | Unknown | SBRT in 73% with median 27 Gy in median 3 fractions; Conventional RT in 27% with median 60 Gy | Median 39.3 months | N.A. |
| Bone = 42.6% | ||||||||
| Both = 22.7% | 2-yr: 63.1%, | |||||||
| Nicosia et al. [32] | 2020 | 109/155 | ≤5 | LN = 100% | 100% | SBRT with median 36 Gy in 4–7 fractions | Median 14.5 months | Median 15 months |
| 1-yr: 54.6% | ||||||||
| 2-yr: 32.8%, | ||||||||
| Oehus et al. [33] | 2020 | 78/185 | ≤5 | LN = 68.2% | Unknown | SBRT in 20.5% | Median: 17.0 months | Median not reached after 16 months of follow-up |
| Bone = 45% | ||||||||
| Visceral = 6.5% | 1-yr: 55.3%, | |||||||
| Franzese et al. [34] | 2019 | 92/119 | ≤5 | LN, bone and visceral | 66% | SBRT with median 42 Gy in 2 to 8 fractions | Median 9.4 months | N.A. |
| 1-yr: 42.8% | ||||||||
| 3-yr: 16.7%, | ||||||||
| Patel et al. [20] | 2019 | 51/64 | ≤3 | Bone = 100% | 82% | SBRT with 24 to 30 Gy in 3 or 5 fractions | Median 24 months in castration sensitive vs 3 months in castration resistant | N.A. |
| Valeriani et al. [28] | 2019 | 29/37 | ≤3 | LN = 5.4% | 0% | SBRT for 16.2% | Median 18,4 months | N.A. |
| Bones = 83.8% | ||||||||
| Other = 10.8% | 2-yr: 38.3% | |||||||
| 3-yr: 8.5%, | ||||||||
| Ong et al. [19] | 2019 | 20/26 | ≤3 | LN = 75% | 100% | SBRT with 30 Gy in 3 fractions and 35 to 40 Gy in 5 fractions | 1-yr: 62% | 1-yr: 70% |
| Bone = 15% | ||||||||
| Both = 10% | ||||||||
| Guler et al. [18] | 2018 | 23/38 | ≤3 | LN = 44.7% | 57% | Hypofractionated RT | 1-yr: 51% | N.A. |
| Bone = 55.3% | ||||||||
| Triggiani et al. [35] | 2017 | 141/209 | ≤3 | LN = 79% | 71% | SBRT with 24 to 45 Gy in 3 to 6 fractions | Median in castration sensitive 17.7 months vs 11 months in castration resistant | Median ADTFS 20.9 months in castration sensitive vs median ADTEFS 22 months in castration resistant |
| Bone = 21% | ||||||||
| Bouman-Wammes et al. [30] | 2017 | 43/54 | ≤4 | LN = 76.6% | 100% | SBRT with 30 or 35 Gy in 3 or 5 fractions | N.A. | Median 15.6 months |
| Bone = 20.9% | ||||||||
| Both = 2.3% | ||||||||
| Pasqualetti et al. [36] | 2016 | 29/45 | ≤3 | LN = 55.5% | 62% | SBRT with 24 Gy or 27 Gy in 1 or 3 fractions | N.A. | Median (systemic therapy free survival) 39.7 months |
| Bone = 44.5% | ||||||||
| Decaestecker et al. [25] | 2014 | 50/70 | ≤3 | LN = 54% | 100% | SBRT with 30 or 50 Gy in 3 or 10 fractions | Median 19 months | Median 25 months |
| 1-yr: 82% | ||||||||
| Bone = 44% | ||||||||
| Visceral = 2% | 1-yr: 64% | 2-yr: 60% | ||||||
| 2-yr: 35%, | ||||||||
| Current study | 2020 | 50/75 | ≤5 | LN = 48% | 70% | SFRS 80% with median 20 Gy | Median 12 months | Median not reached |
| Bone = 46% | ||||||||
| Both = 4% | 1-yr: 54% | 1-yr: 76% | ||||||
| Visceral = 2% | 2-yr: 22% | 2-yr: 60% | ||||||
Abbreviations: ADTFS = androgen deprivation therapy-free survival; LN = lymph node; MDT = metastasis directed therapy; N.A. = not assessed; OMPC = oligometastatic prostate cancer; RT = radiotherapy; SBRT = stereotactic body radiotherapy; SFRS = single fraction radiosurgery.